Shaji Kumar

Shaji Kumar

UNVERIFIED PROFILE

Are you Shaji Kumar?   Register this Author

Register author
Shaji Kumar

Shaji Kumar

Publications by authors named "Shaji Kumar"

Are you Shaji Kumar?   Register this Author

100Publications

1858Reads

31Profile Views

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.

Haematologica 2019 Oct 7;104(10):2061-2074. Epub 2019 Mar 7.

Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.211110DOI Listing
October 2019

Recycling therapies for myeloma: The need for prospective trials.

Authors:
Shaji K Kumar

Cancer 2019 Sep 15;125(17):2920-2922. Epub 2019 May 15.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32177DOI Listing
September 2019

Time Horizons in Cost Analyses.

JAMA 2019 08;322(6):582-583

Centre for Health Economics, University of York, York, England.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2019.7853DOI Listing
August 2019

Fludeoxyglucose F 18 PET/Computed Tomography Evaluation of Therapeutic Response in Multiple Myeloma.

PET Clin 2019 Jul 12;14(3):391-403. Epub 2019 Apr 12.

Department of Radiology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cpet.2019.03.006DOI Listing
July 2019

Surrogate endpoints in randomised controlled trials: a reality check.

Lancet 2019 Jul;394(10195):281-283

Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(19)31711-8DOI Listing
July 2019

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

N Engl J Med 2019 05;380(22):2104-2115

From University of Lille, Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, Lille (T.F.), Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.), Department of Hematology, Hospital Haut Leveque, University Hospital, Pessac (C.H.), Hematology Department, University Hospital, Vandoeuvre lès Nancy (A.P.), Service d'Hématologie, CHU de Toulouse-Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse (M.A.), Department of Hematology, Vendée Hospital, La Roche sur Yon (M.T.), CHU de Caen, Caen (M.M.), Department of Clinical Hematology, Assistance Publique-Hôpitaux de Paris, Necker Hospital, Paris (L.F.), and Department of Hematology, CHU la Miletrie and INSERM CIC 1402, Poitiers (X.L.) - all in France; the Department of Hematology, Mayo Clinic Rochester, Rochester, MN (S.K.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.); Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); University of Calgary, Arnie Charbonneau Cancer Research Institute, Calgary, AB (N.B.), and the Division of Medical Oncology, University of Alberta, Edmonton (C.P.V.) - both in Canada; Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom (S.B.); Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); University of Melbourne, St. Vincent's Hospital, Melbourne, VIC, Australia (H.Q.); University Hospital Heidelberg and National Center of Tumor Diseases (NCT), Heidelberg (H.G.), and the Department of Oncology, Hematology and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg (K.W.) - both in Germany; Department of Medicine-Haematology, National University of Ireland, Galway (M.O.); Florida Cancer Specialists and Research Institute, St. Petersburg (J.R.M.); the Department of Hematology-Oncology, Massachusetts General Hospital, Boston (N.R.); Genmab US, Princeton (T.A.), and Janssen Research and Development, Raritan (J.W., R.K.) - both in New Jersey; Janssen Research and Development, Spring House, PA (C.C., C.M.U., M.Q.); Janssen Research and Development, Beerse, Belgium (R.V.R.); and Levine Cancer Institute-Atrium Health, Charlotte, NC (S.Z.U.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1817249
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1817249DOI Listing
May 2019

The future of myeloma precision medicine: integrating the compendium of known drug resistance mechanisms with emerging tumor profiling technologies.

Leukemia 2019 04 25;33(4):863-883. Epub 2019 Jan 25.

Department of Genetics, Cell Biology & Development, University of Minnesota, Minneapolis, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0362-zDOI Listing
April 2019

Autologous Stem Cell Transplant for IgM-Associated Amyloid Light-Chain Amyloidosis.

Biol Blood Marrow Transplant 2019 03 7;25(3):e108-e111. Epub 2018 Dec 7.

Division of Hematology, Department of Internal Medicine, Mayo Clinic Rochester, Rochester, Minnesota. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.12.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445701PMC
March 2019

Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.

Br J Haematol 2019 Feb 20;184(4):536-546. Epub 2018 Nov 20.

Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15679DOI Listing
February 2019

Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing.

Blood 2019 02 26;133(7):652-659. Epub 2018 Dec 26.

Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-08-825349DOI Listing
February 2019

The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?

Haematologica 2019 Feb;104(2):222-225

Department of Oncology/Hematology, A.O.U. Città della Salute e della Scienza di Torino, Presidio Molinette, Torino, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.206987DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355504PMC
February 2019

Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin.

J Clin Oncol 2019 01 15;37(2):171-173. Epub 2018 Nov 15.

Shaji K. Kumar, MD; Morie A. Gertz, MD; and Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.01398DOI Listing
January 2019

Molecular signatures of multiple myeloma progression through single cell RNA-Seq.

Blood Cancer J 2019 01 3;9(1). Epub 2019 Jan 3.

Genome Analysis Core, Medical Genome Facility, Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41408-018-0160-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318319PMC
January 2019

Targeted Management Strategies in Multiple Myeloma.

Authors:
Shaji K Kumar

Cancer J 2019 Jan/Feb;25(1):59-64

From the Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000353DOI Listing
January 2019

Ixazomib for the treatment of multiple myeloma.

Expert Opin Pharmacother 2018 Dec 13;19(17):1949-1968. Epub 2018 Nov 13.

g Hematology & Medical Oncology , Winship Cancer Institute, Emory University , Atlanta , GA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/14656566.2018.1
Publisher Site
http://dx.doi.org/10.1080/14656566.2018.1528229DOI Listing
December 2018

Timing of treatment of smoldering myeloma: delay until progression.

Authors:
Shaji K Kumar

Blood Adv 2018 11;2(21):3050-3053

Division of Hematology, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018021238DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234369PMC
November 2018

Should we measure clonal circulating plasma cells in light chain amyloidosis?

Oncotarget 2018 Nov 2;9(86):35607-35608. Epub 2018 Nov 2.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26289DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235020PMC
November 2018

Response to 'Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression'.

Leukemia 2018 09 25;32(9):2083-2085. Epub 2018 May 25.

Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0155-4DOI Listing
September 2018

The multiple myelomas - current concepts in cytogenetic classification and therapy.

Nat Rev Clin Oncol 2018 07;15(7):409-421

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41571-018-0018-yDOI Listing
July 2018

Monoclonal Antibodies for Myeloma: Make It Easy!

Authors:
Shaji K Kumar

J Oncol Pract 2018 07;14(7):423-424

Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.18.00350DOI Listing
July 2018

The evolution of stem-cell transplantation in multiple myeloma.

Ther Adv Hematol 2018 May 5;9(5):123-133. Epub 2018 Mar 5.

Professor of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55906, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620718761776DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900826PMC
May 2018

Management of Multiple Myeloma.

Authors:
Shaji K Kumar

J Natl Compr Canc Netw 2018 05;16(5S):624-627

Presented by Shaji K. Kumar, MD, Division of Hematology, Mayo Clinic Cancer Center, Rochester, Minnesota.

View Article

Download full-text PDF

Source
https://jnccn.org/doi/10.6004/jnccn.2018.0040
Publisher Site
http://dx.doi.org/10.6004/jnccn.2018.0040DOI Listing
May 2018